The tyrphostin-AG1296 mechanism of action remains to be defined but involves combined upregulation of BMPRII, SMAD1/5 coactivators, and cAMP response element-binding proteins, leading to an anti-PAH gene expression signature. Here, BMPR2 is linked to pulmonary arterial hypertension.